Submissions from 2024
Impact of Poverty on Stroke Recurrence: A Population-Based Study, Felipe De Los Rios La Rosa
Evaluating the sensitivity of EQ-5D-5L in patients with brain metastases: a secondary analysis of NRG CC001, Minesh Mehta
Comparative evaluation of outcomes amongst different radiosurgery management paradigms for patients with large brain metastasis, Tugce Kutuk, Yanjia Zhang, Eyub Akdemir, Sreenija Yarlagadda, Ranjini Tolakanahalli, Matthew Hall, Alonso La Rosa De Los Rios, D Jay Wieczorek, Cecilia Lee, Haley Appel, Michael McDermott, Yazmin Odia, Manmeet Ahluwalia, Alonso Gutierrez, Minesh Mehta, Rupesh Kotecha, and Robert Press
Survival outcomes of small cell variant bladder cancer: Analysis from a nationwide study, Mohammad Ganiyani, Saba Ahmad, Muni Rubens, Mukesh Roy, Bruno Bastos, Manuel Ozambela Jr, and Murugesan Manoharan
A multicenter phase 1 trial of tucatinib, trastuzumab, and capecitabine with stereotactic radiosurgery in patients with brain metastases from HER-2–positive breast cancer (TUTOR), Manmeet Ahluwalia, Ahmad Ozair, Mainak Bardhan, Dilanis Perche, Muni Rubens, Yazmin Odia, Rupesh Kotecha, Daniel Leon Ariza, Michael McDermott, Ana Cristina Sandoval Leon, Reshma Mahtani, Shreyas Bellur, and David Peereboom
A multicenter, randomized controlled phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE), Manmeet Ahluwalia, Yazmin Odia, and Ahmad Ozair
A Phase I/II Study to assess safety and preliminary evidence of a therapeutic effect of azeliragon combined with stereotactic radiation therapy in patients with brain metasteses, Rupesh Kotecha, Yazmin Odia, Zhijian Chen, Amy K. Starosciak, Alonso La Rosa de los Rios, Susana Herrera, Miguel Ramirez Menendez, Cristina Pow-Sang, Suyen Ramos, Jennifer Perez, Manmeet Ahluwalia, and Minesh Mehta
Dosimetric comparison of magnetic resonance-guided radiation therapy, intensity-modulated proton therapy and volumetric-modulated arc therapy for distal esophageal cancer, Andrew Barsky, Jerry George, Andrew Wroe, Kathryn Mittauer, Adeel Kaiser, Roberto Herrera, Jen Yu, Alonso Gutierrez, Diane Alvarez, James McCulloch, Michael Kasper, Minesh Mehta, and Michael Chuong
Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies, Garje Rohan and Bruno Bastos
Quality assurance of an established online adaptive radiotherapy program: patch and software upgrade, Michael Chuong, Rupesh Kotecha, Yonatan Weiss, Minesh Mehta, Alonso Gutierrez, and Kathryn Mittauer
Implications and interchangeability of meningioma biomarkers for clinical trials and clinical practice, Minesh Mehta
Comparative evaluation of the diagnostic and prognostic performance of CNSide™ versus standard cytology for leptomeningeal disease, Haley Appel, Muni Rubens, Mukesh Roy, Rupesh Kotecha, Matthew Hall, Minesh Mehta, Zhijian Chen, Manmeet Ahluwalia, and Yazmin Odia
Racial Disparities in Blood Pressure at Time of Acute Ischemic Stroke Presentation: A Population Study, Felipe De Los Rios La Rosa
Racial Disparities in Blood Pressure at Time of Acute Ischemic Stroke Presentation: A Population Study, Felipe De Los Rios La Rosa
Diffuse midline glioma, H3K27-altered: Illuminating the dark side of the moon, Yazmin Odia
Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma, Yazmin Odia, Doured Daghistani, and Matthew Hall
Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort, Yazmin Odia and Matthew Hall
In Reply to Cellini and Fiore, Michael Chuong
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma, Yazmin Odia and Minesh Mehta
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma, Yazmin Odia and Minesh Mehta
Implementing Strategies to Recruit and Retain a Diverse Sample of Heart Failure Patients, Sandra Chaparro